{
    "clinical_study": {
        "@rank": "124630", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Combining more than one drug may kill more tumor cells. It is\n      not yet known which combination chemotherapy regimen is most effective for transitional cell\n      cancer of the urothelium.\n\n      PURPOSE: Randomized phase II/III trial to compare different combination chemotherapy\n      regimens in treating patients who have transitional cell cancer of the urothelium."
        }, 
        "brief_title": "Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium", 
        "condition": [
            "Bladder Cancer", 
            "Transitional Cell Cancer of the Renal Pelvis and Ureter", 
            "Urethral Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Urinary Bladder Neoplasms", 
                "Urethral Neoplasms", 
                "Carcinoma, Transitional Cell", 
                "Kidney Neoplasms", 
                "Ureteral Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Compare the antitumor activity of gemcitabine and carboplatin vs methotrexate,\n           carboplatin, and vinblastine in patients with transitional cell cancer of the\n           urothelium who are ineligible for cisplatin-based chemotherapy.\n\n        -  Compare the toxicity and acute and intermediate (1-2 years) side effects of these\n           regimens in these patients.\n\n        -  Compare the complete response rates, progression-free survival, and overall survival of\n           patients treated with these regimens.\n\n        -  Compare the symptoms and quality of life of patients treated with these regimens.\n\n      OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two\n      treatment arms.\n\n        -  Arm I: Patients receive methotrexate* IV and vinblastine IV on days 1, 15, and 22 and\n           carboplatin IV over 1 hour on day 1. Courses repeat every 28 days in the absence of\n           disease progression or unacceptable toxicity.\n\n        -  Arm II: Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and carboplatin\n           IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease\n           progression or unacceptable toxicity.\n\n      NOTE: * Methotrexate is omitted for patients with pleural effusion or ascites until complete\n      resolution and for patients with a glomerular filtration rate less than 30 mL/min or\n      creatinine greater than 2 mg/dL\n\n      Patients in either arm who achieve a complete response (CR) receive 2 additional courses of\n      chemotherapy beyond CR.\n\n      Quality of life is assessed at baseline, after every 2 courses of chemotherapy, and within 6\n      weeks of completion of therapy.\n\n      Patients are followed within 6 weeks, every 3 months for 1 year, and then every 6 months\n      thereafter.\n\n      PROJECTED ACCRUAL: A total of 156 patients (78 per treatment arm) will be accrued for the\n      phase II portion of this study. A total of 225 patients will be accrued for the phase II +\n      III portions of this study within 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed transitional cell cancer of the urothelium, including the\n             renal pelvis, ureters, urinary bladder, and urethra, meeting 1 of the following\n             criteria:\n\n               -  Unresected positive lymph node\n\n               -  Distant metastases (M1, stage IV)\n\n               -  Unresectable primary bladder cancer (T3-4)\n\n          -  Measurable disease\n\n          -  Ineligible for cisplatin-based chemotherapy and presenting with the following:\n\n               -  WHO performance status 2 AND/OR\n\n               -  Glomerular filtration rate greater than 30 mL/min but less than 60 mL/min\n\n          -  No brain metastases or other CNS lesions\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  See Disease Characteristics\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  WBC at least 4,000/mm^3\n\n          -  Platelet count at least 125,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin no greater than 1.25 times normal\n\n          -  AST/ALT no greater than 3 times normal (5 times normal if liver metastases are\n             present)\n\n        Renal:\n\n          -  See Disease Characteristics\n\n          -  Calcium normal\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception during and for 6 months after study\n             participation\n\n          -  No psychological, familial, sociological, or geographical condition that would\n             preclude study participation\n\n          -  No other prior or concurrent malignancy except cured basal cell skin cancer or\n             carcinoma in situ of the cervix\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No prior systemic biologic therapy\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  No prior systemic cytotoxic therapy (including adjuvant and neoadjuvant chemotherapy)\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  At least 3 months since prior radiotherapy\n\n          -  Prior radiotherapy to study lesions allowed if there is evidence of disease\n             progression\n\n        Surgery:\n\n          -  Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "238", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 10, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00014274", 
            "org_study_id": "EORTC-30986", 
            "secondary_id": "EORTC-GU-30986"
        }, 
        "intervention": [
            {
                "intervention_name": "carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "gemcitabine hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "methotrexate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "vinblastine sulfate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methotrexate", 
                "Gemcitabine", 
                "Vinblastine", 
                "Carboplatin"
            ]
        }, 
        "keyword": [
            "stage III bladder cancer", 
            "stage IV bladder cancer", 
            "transitional cell carcinoma of the bladder", 
            "anterior urethral cancer", 
            "posterior urethral cancer", 
            "urethral cancer associated with invasive bladder cancer", 
            "metastatic transitional cell cancer of the renal pelvis and ureter", 
            "regional transitional cell cancer of the renal pelvis and ureter"
        ], 
        "lastchanged_date": "June 11, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/EORTC-GU-30986"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Salzburg", 
                        "country": "Austria", 
                        "zip": "A-5020"
                    }, 
                    "name": "St. Johanns-Spital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria", 
                        "zip": "A-1100"
                    }, 
                    "name": "Ludwig Boltzmann Institute for Applied Cancer Research at Kaiser Franz Josef Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aalst", 
                        "country": "Belgium", 
                        "zip": "B-9300"
                    }, 
                    "name": "Onze Lieve Vrouw Ziekenhuis Aalst"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1000"
                    }, 
                    "name": "Institut Jules Bordet"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edegem", 
                        "country": "Belgium", 
                        "zip": "B-2650"
                    }, 
                    "name": "Universitair Ziekenhuis Antwerpen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kortrijk", 
                        "country": "Belgium", 
                        "zip": "8500"
                    }, 
                    "name": "AZ Groeninge - Oncologisch Centrum"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Copenhagen", 
                        "country": "Denmark", 
                        "zip": "2100"
                    }, 
                    "name": "Rigshospitalet - Copenhagen University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nuernberg", 
                        "country": "Germany", 
                        "zip": "D-90419"
                    }, 
                    "name": "Klinikum Nuernberg - Klinikum Nord"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary", 
                        "zip": "1125"
                    }, 
                    "name": "National Institute of Oncology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zerifin", 
                        "country": "Israel", 
                        "zip": "70300"
                    }, 
                    "name": "Assaf Harofeh Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palermo", 
                        "country": "Italy", 
                        "zip": "90145"
                    }, 
                    "name": "Universita Di Palermo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Varese", 
                        "country": "Italy", 
                        "zip": "21100"
                    }, 
                    "name": "Ospedale di Circolo e Fondazione Macchi"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "'s-Hertogenbosch", 
                        "country": "Netherlands", 
                        "zip": "5211 NL"
                    }, 
                    "name": "Jeroen Bosch Ziekenhuis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1066 CX"
                    }, 
                    "name": "Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1105 AZ"
                    }, 
                    "name": "Academisch Medisch Centrum at University of Amsterdam"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leiden", 
                        "country": "Netherlands", 
                        "zip": "2300 CA"
                    }, 
                    "name": "Leiden University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nijmegen", 
                        "country": "Netherlands", 
                        "zip": "NL-6500 HB"
                    }, 
                    "name": "Universitair Medisch Centrum St. Radboud - Nijmegen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3000 CA"
                    }, 
                    "name": "University Medical Center Rotterdam at Erasmus Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "zip": "3584 CX"
                    }, 
                    "name": "University Medical Center Utrecht"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warsaw", 
                        "country": "Poland", 
                        "zip": "02-781"
                    }, 
                    "name": "Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08036"
                    }, 
                    "name": "Hospital Clinic de Barcelona"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08025"
                    }, 
                    "name": "Hospital de la Santa Cruz i Sant Pau"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "Vall d'Hebron University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28040"
                    }, 
                    "name": "Hospital Universitario San Carlos"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46009"
                    }, 
                    "name": "Instituto Valenciano De Oncologia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Southampton", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "SO16 6YD"
                    }, 
                    "name": "Southampton General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Southampton", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "SO14 0YG"
                    }, 
                    "name": "Leeds Cancer Centre at St. James's University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Southampton", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "SO14 0YG"
                    }, 
                    "name": "Royal South Hants Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sutton", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "SM2 5PT"
                    }, 
                    "name": "Royal Marsden - Surrey"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Belgium", 
                "Denmark", 
                "Germany", 
                "Hungary", 
                "Israel", 
                "Italy", 
                "Netherlands", 
                "Poland", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "official_title": "Randomized Phase II/III Study Assessing Gemcitabine/Carboplatin And Methotrexate/Carboplatin/Vinblastine In Previously Untreated Patients With Advanced Urothelial Cancer Ineligible For Cisplatin Based Chemotherapy", 
        "overall_official": {
            "affiliation": "Klinikum Nuernberg - Klinikum Nord", 
            "last_name": "Gerwin Kaiser, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "March 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Duration of survival", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00014274"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": [
            {
                "PMID": "22162575", 
                "citation": "De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna I, Collette S, Lorent J, de Wit R, Sylvester R. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012 Jan 10;30(2):191-9. doi: 10.1200/JCO.2011.37.3571. Epub 2011 Dec 12. PubMed PMID: 22162575; PubMed Central PMCID: PMC3255563."
            }, 
            {
                "PMID": "19786668", 
                "citation": "De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Skoneczna I, Marreaud S, de Wit R, Sylvester R. Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer \"Unfit\" for Cisplatin-Based Chemotherapy: Phase II--Results of EORTC Study 30986. J Clin Oncol. 2009 Sep 28; [Epub ahead of print]"
            }, 
            {
                "citation": "De Santis M, Bellmunt J, Mead B, et al.: Randomized phase II/III study assessing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in previously untreated patients (pts) with advanced urothelial cancer ineligible for cisplatin based chemotherapy: phase II results of. [Abstract] American Society of Clinical Oncology 2008 Genitourinary Cancers Symposium, Feb 14-16, 2008, San Francisco, CA. A-288, 2008."
            }
        ], 
        "secondary_outcome": [
            {
                "measure": "Response as assessed by RECIST criteria", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Toxicity as assessed by CTC v2", 
                "safety_issue": "Yes"
            }
        ], 
        "source": "European Organisation for Research and Treatment of Cancer - EORTC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "European Organisation for Research and Treatment of Cancer - EORTC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2001", 
        "study_design": "Allocation: Randomized, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }, 
    "geocoordinates": {
        "AZ Groeninge - Oncologisch Centrum": "50.831 3.264", 
        "Academisch Medisch Centrum at University of Amsterdam": "52.37 4.895", 
        "Assaf Harofeh Medical Center": "31.963 34.848", 
        "Hospital Clinic de Barcelona": "41.388 2.17", 
        "Hospital Universitario San Carlos": "40.417 -3.7", 
        "Hospital de la Santa Cruz i Sant Pau": "41.388 2.17", 
        "Institut Jules Bordet": "50.85 4.352", 
        "Instituto Valenciano De Oncologia": "39.47 -0.377", 
        "Jeroen Bosch Ziekenhuis": "51.698 5.317", 
        "Klinikum Nuernberg - Klinikum Nord": "49.445 11.087", 
        "Leeds Cancer Centre at St. James's University Hospital": "50.91 -1.404", 
        "Leiden University Medical Center": "52.16 4.494", 
        "Ludwig Boltzmann Institute for Applied Cancer Research at Kaiser Franz Josef Hospital": "48.208 16.374", 
        "Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology": "52.23 21.012", 
        "National Institute of Oncology": "47.498 19.041", 
        "Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital": "52.37 4.895", 
        "Onze Lieve Vrouw Ziekenhuis Aalst": "50.938 4.041", 
        "Ospedale di Circolo e Fondazione Macchi": "45.818 8.826", 
        "Rigshospitalet - Copenhagen University Hospital": "55.676 12.568", 
        "Royal Marsden - Surrey": "51.361 -0.194", 
        "Royal South Hants Hospital": "50.91 -1.404", 
        "Southampton General Hospital": "50.91 -1.404", 
        "St. Johanns-Spital": "47.809 13.055", 
        "Universita Di Palermo": "38.116 13.361", 
        "Universitair Medisch Centrum St. Radboud - Nijmegen": "51.843 5.855", 
        "Universitair Ziekenhuis Antwerpen": "51.153 4.438", 
        "University Medical Center Rotterdam at Erasmus Medical Center": "51.924 4.482", 
        "University Medical Center Utrecht": "52.09 5.11", 
        "Vall d'Hebron University Hospital": "41.388 2.17"
    }
}